SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.17+3.9%Dec 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (3007)2/27/2001 9:54:48 AM
From: Biomaven  Read Replies (2) of 52153
 
Michael,

<<SCIO>>

Natrecor estimates of $300-$500 million in peak sales

That would of course send SCIO way, way up. It would likely produce profits in the $100m to $200m range (about $2.50 to $5.00 per share) given their favorable marketing deal (a 90%-10% split). However, by going with QTRN as the marketing partner rather than a big pharma, they have likely reduced their peak sales quite a bit. Further, it is tough to change long-established ER practice, and so early sales could be slow.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News